Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success
Company Hails ‘Quite Remarkable’ Phase III Results
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.
